Alnylam Pharmaceuticals (ALNY) Assets (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Assets of $5.1 billion for Q1 2026, up 21.73% year-on-year from $4.2 billion in Q1 2025, and up 3.29% on a QoQ basis from $5.0 billion in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of Assets data on file, last reported at $5.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 21.73% year-over-year to $5.1 billion; the trailing twelve-month figure through Mar 2026 stood at $5.1 billion (up 21.73% YoY), and the FY2025 full-year result was $5.0 billion, up 17.13% from the prior year.
- Assets for Q1 2026 stood at $5.1 billion, up from $5.0 billion in the prior quarter.
- Across five years, Assets topped out at $5.1 billion in Q1 2026 and bottomed at $3.3 billion in Q2 2022.
- The 5-year median for Assets is $3.8 billion (2023), against an average of $4.0 billion.
- The widest annual swing landed in 2022, when Assets dropped 5.1%; it then advanced 21.73% in 2026.
- A 5-year view of Assets shows it stood at $3.5 billion in 2022, then grew by 7.99% to $3.8 billion in 2023, then increased by 10.71% to $4.2 billion in 2024, then advanced by 17.13% to $5.0 billion in 2025, then grew by 3.29% to $5.1 billion in 2026.
- The last three Assets figures came in at $5.1 billion (Q1 2026), $5.0 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 2.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.13 Bn |
| Dec 31, 2025 | 4.97 Bn |
| Sep 30, 2025 | 4.85 Bn |
| Jun 30, 2025 | 4.57 Bn |
| Mar 31, 2025 | 4.21 Bn |
| Dec 31, 2024 | 4.24 Bn |
| Sep 30, 2024 | 4.21 Bn |
| Jun 30, 2024 | 4.01 Bn |
| Mar 31, 2024 | 3.82 Bn |
| Dec 31, 2023 | 3.83 Bn |
| Sep 30, 2023 | 3.84 Bn |
| Jun 30, 2023 | 3.40 Bn |
| Mar 31, 2023 | 3.39 Bn |
| Dec 31, 2022 | 3.55 Bn |
| Sep 30, 2022 | 3.54 Bn |
| Jun 30, 2022 | 3.33 Bn |
| Mar 31, 2022 | 3.43 Bn |
| Dec 31, 2021 | 3.64 Bn |
| Sep 30, 2021 | 3.47 Bn |
| Jun 30, 2021 | 3.51 Bn |
| Mar 31, 2021 | 3.26 Bn |
| Dec 31, 2020 | 3.41 Bn |
| Sep 30, 2020 | 3.31 Bn |
| Jun 30, 2020 | 3.37 Bn |
| Mar 31, 2020 | 2.28 Bn |
| Dec 31, 2019 | 2.40 Bn |
| Sep 30, 2019 | 2.54 Bn |
| Jun 30, 2019 | 2.72 Bn |
| Mar 31, 2019 | 2.01 Bn |
| Dec 31, 2018 | 1.57 Bn |
| Sep 30, 2018 | 1.68 Bn |
| Jun 30, 2018 | 1.79 Bn |
| Mar 31, 2018 | 1.92 Bn |
| Dec 31, 2017 | 1.99 Bn |
| Sep 30, 2017 | 1.36 Bn |
| Jun 30, 2017 | 1.43 Bn |
| Mar 31, 2017 | 1.13 Bn |
| Dec 31, 2016 | 1.26 Bn |
| Sep 30, 2016 | 1.31 Bn |
| Jun 30, 2016 | 1.38 Bn |
| Mar 31, 2016 | 1.32 Bn |
| Dec 31, 2015 | 1.39 Bn |
| Sep 30, 2015 | 1.44 Bn |
| Jun 30, 2015 | 1.53 Bn |
| Mar 31, 2015 | 1.63 Bn |
| Dec 31, 2014 | 1.08 Bn |
| Sep 30, 2014 | 986.36 Mn |
| Jun 30, 2014 | 1.03 Bn |
| Mar 31, 2014 | 1.08 Bn |
| Dec 31, 2013 | 420.53 Mn |
| Sep 30, 2013 | 447.50 Mn |
| Jun 30, 2013 | 462.56 Mn |
| Mar 31, 2013 | 471.58 Mn |
| Dec 31, 2012 | 287.52 Mn |
| Sep 30, 2012 | 322.35 Mn |
| Jun 30, 2012 | 318.48 Mn |
| Mar 31, 2012 | 340.30 Mn |
| Dec 31, 2011 | 281.92 Mn |
| Sep 30, 2011 | 310.22 Mn |
| Jun 30, 2011 | 340.83 Mn |
| Mar 31, 2011 | 369.05 Mn |
| Dec 31, 2010 | 393.27 Mn |
| Sep 30, 2010 | 412.61 Mn |
| Jun 30, 2010 | 440.18 Mn |
| Dec 31, 2009 | 481.39 Mn |